WO2013088368A3 - Use of the mmp-12 protein in the prevention and/or treatment of aged or senescent skin - Google Patents

Use of the mmp-12 protein in the prevention and/or treatment of aged or senescent skin Download PDF

Info

Publication number
WO2013088368A3
WO2013088368A3 PCT/IB2012/057237 IB2012057237W WO2013088368A3 WO 2013088368 A3 WO2013088368 A3 WO 2013088368A3 IB 2012057237 W IB2012057237 W IB 2012057237W WO 2013088368 A3 WO2013088368 A3 WO 2013088368A3
Authority
WO
WIPO (PCT)
Prior art keywords
aged
mmp
protein
prevention
treatment
Prior art date
Application number
PCT/IB2012/057237
Other languages
French (fr)
Other versions
WO2013088368A2 (en
Inventor
Isabelle Castiel
Audrey Gueniche
Original Assignee
L'oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L'oreal filed Critical L'oreal
Publication of WO2013088368A2 publication Critical patent/WO2013088368A2/en
Publication of WO2013088368A3 publication Critical patent/WO2013088368A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24065—Macrophage elastase (3.4.24.65), i.e. metalloelastase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the cosmetic use of an effective amount of at least one active agent consisting of a polypeptide having at least 80% amino acid identity with a metalloproteinase MMP-12 of sequence chosen from SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3 indicated hereinafter, or a C-terminal fragment of this polypeptide, for preventing and/or treating aged or senescent skin.
PCT/IB2012/057237 2011-12-14 2012-12-12 Use of the mmp-12 protein in the prevention and/or treatment of aged or senescent skin WO2013088368A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR1161623 2011-12-14
FR1161623A FR2984130A1 (en) 2011-12-14 2011-12-14 USE OF PROTEIN MMP-12 IN PREVENTING AND / OR TREATING OLD OR SENESCENT SKINS.
US201261608947P 2012-03-09 2012-03-09
US61/608,947 2012-03-09

Publications (2)

Publication Number Publication Date
WO2013088368A2 WO2013088368A2 (en) 2013-06-20
WO2013088368A3 true WO2013088368A3 (en) 2014-03-06

Family

ID=45926674

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/057237 WO2013088368A2 (en) 2011-12-14 2012-12-12 Use of the mmp-12 protein in the prevention and/or treatment of aged or senescent skin

Country Status (2)

Country Link
FR (1) FR2984130A1 (en)
WO (1) WO2013088368A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087325A2 (en) * 2002-04-08 2003-10-23 The Brigham And Women's Hospital, Inc. Methods and compositions for preventing and treating microbial infections
WO2009111083A2 (en) * 2008-03-06 2009-09-11 Halozyme, Inc. In vivo temporal control of activ at able matrix- degrading enzymes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0852949A3 (en) 1997-03-31 1999-08-04 Shiseido Company Limited Use of alpha-amino-acids for enhancing desmosomal degradation or stratum corneum desquamation
FR2818547B1 (en) 2000-12-22 2006-11-17 Oreal NOVEL C-GLYCOSIDE DERIVATIVES AND USE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087325A2 (en) * 2002-04-08 2003-10-23 The Brigham And Women's Hospital, Inc. Methods and compositions for preventing and treating microbial infections
WO2009111083A2 (en) * 2008-03-06 2009-09-11 Halozyme, Inc. In vivo temporal control of activ at able matrix- degrading enzymes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SEO ET AL: "Thermal aging: A new concept of skin aging", JOURNAL OF DERMATOLOGICAL SCIENCE SUPPLEMENT, ELSEVIER, NL, vol. 2, no. 1, 14 November 2006 (2006-11-14), pages S13 - S22, XP005768170, ISSN: 1574-0757, DOI: 10.1016/J.DESCS.2006.08.002 *

Also Published As

Publication number Publication date
WO2013088368A2 (en) 2013-06-20
FR2984130A1 (en) 2013-06-21

Similar Documents

Publication Publication Date Title
MX360208B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX360211B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
EP2532365A4 (en) Pharmaceutical composition for treatment and/or prevention of cancer
MY167232A (en) Polypeptides binding to human complement c5
MX357505B (en) Medicinal composition for treating and/or preventing cancer.
NZ623576A (en) Tfpi inhibitors and methods of use
BR112012018951C8 (en) monoclonal antibody, pharmaceutical composition, pharmaceutical combination, use of an antibody, use of a pharmaceutical composition and use of a pharmaceutical combination
PE20140617A1 (en) ACID ALPHA GLUCOSIDASE MODIFIED WITH ACCELERATED PROCESSING
RU2017116973A (en) METHODS OF APPLICATION AND COMPOSITION OF NEUREGULINS FOR PREVENTION, TREATMENT OR SLOW-UP OF HEART FAILURE WITH THE SAVED EMISSION FRACTION
UA115436C2 (en) Anticancer fusion protein
MX339203B (en) Anticancer fusion protein.
WO2019045248A3 (en) Peptide exhibiting wrinkle-improving activity and uses thereof
NZ708091A (en) Stabilized insulin-like growth factor polypeptides
WO2006135493A3 (en) A composition for wound healing and use thereof
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
WO2007014253A3 (en) Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure
CA3010564A1 (en) An antibacterial composition and a method of treating staphylococcal infections with the antibacterial composition
WO2013088371A3 (en) Use of the mmp-12 protein in the prevention and/or treatment of dandruff conditions of the scalp
NZ711281A (en) Short bio-active peptides for promoting wound healing
WO2012143477A3 (en) Anticancer fusion protein
HK1121383A1 (en) Wound healing agent and composition
MX2017008505A (en) Composition.
WO2013088368A3 (en) Use of the mmp-12 protein in the prevention and/or treatment of aged or senescent skin
WO2015108856A3 (en) Methods for enhancing the delivery of active agents
WO2013088369A3 (en) Use of the protein mmp-12 in the prevention and/or treatment of greasy skin and/or greasy-prone skin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12815834

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12815834

Country of ref document: EP

Kind code of ref document: A2